Odonate Therapeutics, Inc.
ODT evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Lead Asset:
- tesetaxel (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ODT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
tesetaxel (Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate · 2 clinical trials for Odonate Therapeutics, Inc..
Run Odonate Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Odonate Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Odonate Therapeutics, Inc.'s lead drug candidate?
Odonate Therapeutics, Inc.'s most advanced tracked candidate is tesetaxel (Phase 3) for Metastatic breast cancer (MBC).
Who is the CEO of Odonate Therapeutics, Inc.?
Kevin Tang is the chief executive officer of Odonate Therapeutics, Inc. (ODT).
What therapeutic areas does Odonate Therapeutics, Inc. focus on?
Odonate Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.